Medication info

Metformin and Sitagliptin Tablet 50/1000 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Dark red oval film-coated tablet
Packaging
Company packaging unit
Approval status
Approval withdrawn

MFDS item code 201506303 · Approved 2015.09.01

This product's status changed to Approval withdrawn on 2023.07.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should take the patient's blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is an adjunct to diet and exercise to help control blood sugar in patients with type 2 diabetes. If individuals who have not previously taken diabetes medications find it difficult to control their blood sugar, this medication can be used alone. It is also administered when blood sugar control is inadequate with monotherapy of either metformin or sitagliptin, or when replacing the combination therapy of both medications. If blood sugar is not controlled with a combination of metformin and sulfonylurea, sulfonylurea can be combined with this medication. Similarly, if the combination of metformin and thiazolidinedione is ineffective, this medication can be used together with thiazolidinedione. Lastly, if control is lacking with combination therapy of insulin and metformin, this medication can be used concurrently with insulin to improve blood sugar control.

Dosage and Administration

Adult dosage

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should take the patient's blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication is used for the treatment of diabetes and helps to control blood sugar. Severe allergic reactions can occur during the use of this medication, so if symptoms such as skin rash, hives, difficulty breathing, or swelling of the face or neck occur, it should be stopped immediately and medical advice should be sought. There is a risk of serious pancreatic inflammation known as pancreatitis, so any symptoms including abdominal pain, nausea, vomiting, or fever should be reported to a healthcare professional immediately. Patients with poor kidney function or heart problems may face risks when taking this medication, so it must be used only after consulting with a doctor. The use of this medication should be temporarily stopped before and after examinations using iodine contrast agents, and resumption should only occur after confirming normal kidney function. It is safer for women who are pregnant or may become pregnant, as well as nursing mothers, to avoid this medication. Irregular meals, vigorous exercise, and concurrent use with certain medications can increase the risk of side effects such as hypoglycemia or lactic acidosis, requiring careful monitoring. This medication may cause gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain) and headaches, as well as cold symptoms. When taken with other antihyperglycemic agents, hypoglycemic symptoms may occur, thus blood sugar levels should be frequently monitored and dosage adjustments made as necessary. Lactic acidosis, a rare but very serious side effect, can happen; symptoms such as sudden muscle aches, shortness of breath, fatigue, or abdominal pain require immediate medical consultation. Long-term use of this medication may result in decreased Vitamin B12 levels, hence regular blood tests are recommended. Before surgery, this medication should be discontinued and restarted only after the patient's condition has stabilized. Elderly patients may have reduced kidney function, so regular kidney function monitoring and the lowest effective dose should be administered. In case of overdose, immediate medical care should be sought, and in some cases, blood dialysis may be necessary. Alcohol consumption during the use of this medication is best avoided, and any unusual symptoms associated with the medication should be discussed with a physician immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 33 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rash
  • urticaria
  • cutaneous vasculitis
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • itchiness
  • constipation
  • gastrointestinal gas distension
  • abdominal discomfort
  • dyspepsia
  • asthenia
  • severe and debilitating arthralgia
  • bullous pemphigoid
  • severe hypoglycemia
  • anemia
  • dermatitis
  • appetite loss
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that does not allow air to enter and kept at room temperature between 1 and 30 degrees Celsius. Storing it this way can maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

Dark red oval film-coated tablet

Package unit

Company packaging unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.